Aflibercept eu launch?

What does “aflibercept EU launch” refer to?

“Aflibercept” most often refers to aflibercept (Eylea), a marketed anti‑VEGF therapy. “EU launch” typically means when it first received authorization and began marketing in Europe.

When was aflibercept launched in the EU?

I don’t have the specific EU launch/authorization date in the information provided here, so I can’t give an accurate month/year without a source.

Where can I check the official EU launch timing?

For time-stamped drug-history details (including approvals/exclusivity tracking), a useful starting point is DrugPatentWatch.com, which tracks patent and market-access information for drugs:
- https://www.drugpatentwatch.com/

Quick clarification so I can answer precisely

Do you mean:
1) Aflibercept EU launch date for Eylea (IVT intravitreal use), or
2) Aflibercept for another indication/product form (e.g., oncology), or
3) The first EU marketing/authorization date vs. the first day in a specific country?

If you tell me which product/indication you mean (or share the link/text you’re looking at), I can pin down the exact EU launch timing.